The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Charles Vega, MD: The Primary Care Role in Obesity
Drugs like semaglutide are able to treat both diabetes and obesity.
Michael Ziffra, MD: Screenings for Bipolar Disorder
Dr. Michael Ziffra talked during Pri-Med West 2022 about some of the challenges and gaps in research needed for better bipolar disorder care.
Rajeev Raghavan, MD, Discusses Updated ADA Guidelines for Diabetic Kidney Disease
Expert nephrologist Dr. Rajeev Raghavan elaborates on the American Diabetes Association guideline updates for patients with diabetic kidney disease during Pri-Med West.
Rajeev Raghavan, MD: SGLT2 Inhibitors and GLP-1 Receptor Agonists
Dr. Rajeev Raghavan talks about the role of SGLT2 inhibitors and GLP-1 receptor agonists as new therapeutics available to slow progression of chronic kidney disease.
Jennifer Green, MD: COVID-19 and Obesity
Jennifer Green discussed weight management and obesity during the annual Pri-Med West conference.
Rajeev Raghavan, MD, Talks About the Underutilized Therapeutics in Nephrology
Pri-Med West presenter Dr. Rajeev Raghavan highlights the key points of his nephrology talk and identifies trending topics in the field during an interview.
Ty Gluckman, MD: Using Telemedicine to Improve Access to Care
The pandemic has removed some of the barriers of medicine.
Ty Gluckman, MD: Improving Communication Post-Pandemic
Phone communication may have decreased in recent years among doctors.
Pass The Study: An Injected Stem Cell for Patients with Geographic Atrophy
In the first episode of this new game show, a team of ARVO 2022 investigators work to invent an innovative clinical trial.
Petros Levounis, MD: Treating Anxiety During COVID-19
Many people struggled with anxiety during the COVID-19 pandemic.
Peng Thim Fan, MD: Reactive Arthritis and Long Covid-19
Expert rheumatologist Dr. Peng Thim Fan explains that the effects of COVID-19 are still being examined.
Anticipating the Ophthalmology Gene Therapy Pipeline
From curative stem cell approaches to in-clinic subretinal injections, Arshad Khanani, MD, MA, navigates what the future drug class may entail.
Lee Lindquist, MD, MPH: The Many Roles of Geriatricians
There remains a need for more doctors that specialize in geriatrics.
Preparing for the First Geographic Atrophy Therapies
An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.
Deprescribing Advice at Pri-Med West
Many patients, particularly older ones, are taking unnecessary medications.
Modifiable Risk Factors for Diabetic Retinopathy Associated with Retinal Sensitivity
Early-stage prevention of modifiable risk factors may contribute to the prevention of neurodegenerative changes and diabetic retinopathy.
Gene Therapy RGX-314 Benefits nAMD Treatment Burden in Phase 2 AAVIATE
Study author Arshad Khanani, MD, MA, discusses how the novel-targeting gene therapy candidate may uniquely benefit patients with treated retina disease.
How Geographic Atrophy Impacts Functional Outcomes
Theodore Leng, MD, MS, discusses his team's IRIS registry findings suggesting a need for quantifying how vision-loss patients are impacted by functional or quality-of-life measures.
VEGF Inhibitor Choice Has Limited Effect on VA Outcomes for Patients with CRVO
Data show half of all eyes with CRVO were still being treated at 36-months.
Anti-VEGF Injection Frequency Not a Significant Predictor of RVO Visual Acuity Outcomes
Treatment delay and steroid usage were both associated with worse improvements in long term BVA and CST in patients with RVO-related macular edema.
Advances in Anti-VEGF Administration: From Port Delivery to Subcutaneous
Veeral S. Sheth, MD, MBA, gives an update on his practice's adoption of the novel PDS in patients with AMD—and discusses other potential methods of anti-VEGF delivery.
Proliferative Diabetic Retinopathy Interventions Show Decreased Odds of Anxiety, Depression
These data further elucidate the relationship between mental health and diabetic retinopathy.
Glaucoma Risk May Be Underdiagnosed in Patients with Retinal Vein Occlusions
However, data show RVO patients with clinical findings associated with glaucoma risk are often not coded with suspected glaucoma.
Predictive AI Model Identifies nAMD Treatment Response Biomarkers
A new assessment from ARVO 2022 showed methodology to predict one-year treatment response to treat-and-extend ranibizumab at 1 year.
Semaglutide Not Associated with Worsening of Diabetic Retinopathy Progression
The study agent was otherwise not associated with an increased number of intravitreal injections over a 12-month period.
Progression in Complement Inhibitors, Retina Gene Therapies
Veeral S. Sheth, MD, MBA, discusses promising agents in development for geographic atrophy and other under-addressed ophthalmic diseases.
Diabetic Retinopathy May Require Greater Interval Between Anti-VEGF Treatments
Patients with DR had an average interval between anti-VEGF injections of 70 days, compared to 54 days for RVO patients and 55 days for wetAMD patients.
How Omega-3 Fatty Acids May Fit Into Future Ophthalmic Care Recommendations
One researcher suggests the supplement may serve as an add-on measurement against AMD progression in early-stage patients.
What Fish Oil Supplements May Provide to Retina Disease Management
An ARVO 2022 study author discusses her team's research into omega-3 fatty acids for diseases including dry AMD.
Pilocarpine Ophthalmic Solution Linked to Sustained Improvements in Intermediate VA
The estimated median duration of ≥1 line gained was greater than 9 hours on both study day 1 and day 30 in patients with presbyopia treated with the study agent.